0.20
+0.015(+8.33%)
Currency In USD
Address
960 San Antonio Road
Palo Alto, CA 94303
United States of America
Phone
650 516 4310
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
115
First IPO Date
March 05, 2021
| Name | Title | Pay | Year Born |
| Dr. Henry H. Ji Ph.D. | Chief Executive Officer, President & Executive Chairman | 1.26M | 1964 |
| Mr. Suresh K. Khemani | Senior Vice President, Chief Commercial Officer & GM of Scilex Pharma | 456,820 | 1960 |
| Dr. Dmitri V. Lissin M.D. | Senior Vice President of Clinical Development and Medical Affairs & Interim Chief Medical Officer | 528,826 | 1959 |
| Mr. Stephen Ma | Senior Vice President, Chief Financial Officer, Chief Operating Officer, Corporate Secretary & Director | 613,821 | 1972 |
| Dr. Suketu D. Desai Ph.D. | Interim Chief Technical Officer & Senior Vice President | 0 | 1965 |
| Ms. Gigi DeGuzman | Vice President & Chief People Officer | 0 | N/A |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.